FR7337M
(bg)
*
|
1968-01-11 |
1969-10-13 |
|
|
FR2096868B1
(bg)
*
|
1970-07-08 |
1974-02-01 |
Roussel Uclaf |
|
GB1318300A
(en)
*
|
1970-12-09 |
1973-05-23 |
Labaz |
Indole derivatives nad compositions containing the same
|
GB1436771A
(en)
*
|
1973-02-16 |
1976-05-26 |
Labaz |
Indole derivatives and process for preparing the same
|
US4021448A
(en)
*
|
1975-10-21 |
1977-05-03 |
Sterling Drug Inc. |
2-Substituted-indole-1-lower-alkanecarboxamides
|
US4233312A
(en)
*
|
1976-01-21 |
1980-11-11 |
Roussel Uclaf |
Esters of indole-1-acetic acid and analgesic use thereof
|
SE421917B
(sv)
*
|
1976-01-21 |
1982-02-08 |
Roussel Uclaf |
Analogiforfarande for framstellning av nya derivat av 2-metyl-1-indolyl-ettikssyra med terapeutisk verkan
|
US4478842A
(en)
*
|
1981-11-19 |
1984-10-23 |
Ciba-Geigy Corporation |
N-Substituted-2-pyridylindoles
|
US4460777A
(en)
*
|
1981-11-19 |
1984-07-17 |
Ciba-Geigy Corporation |
N-Substituted-2-pyridylindoles
|
US4511573A
(en)
*
|
1983-05-17 |
1985-04-16 |
Ciba-Geigy Corporation |
3-Substituted-2-(heteroaryl) indoles
|
US5229413A
(en)
*
|
1989-05-05 |
1993-07-20 |
G. D. Searle & Co. |
Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
|
US5137910A
(en)
*
|
1989-05-05 |
1992-08-11 |
C.D. Searle & Co. |
Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
|
WO1993005019A1
(en)
*
|
1991-09-11 |
1993-03-18 |
Fujisawa Pharmaceutical Co., Ltd. |
Indole derivatives as 5-alpha-reductase inhibitor
|
GB9204024D0
(en)
*
|
1992-02-25 |
1992-04-08 |
Fujisawa Pharmaceutical Co |
Indole derivatives
|
GB9204365D0
(en)
*
|
1992-02-28 |
1992-04-08 |
Pfizer Ltd |
Indoles
|
ES2099007B1
(es)
*
|
1993-07-16 |
1997-12-01 |
Pfizer Res & Dev |
Derivados de indol.
|
GB9716657D0
(en)
|
1997-08-07 |
1997-10-15 |
Zeneca Ltd |
Chemical compounds
|
GB9803226D0
(en)
*
|
1998-02-17 |
1998-04-08 |
Zeneca Ltd |
Chemical compounds
|
MXPA02003122A
(es)
*
|
1998-03-31 |
2004-04-21 |
Inst For Pharm Discovery Inc |
Acidos indolalcanoicos substituidos.
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
GB9902452D0
(en)
|
1999-02-05 |
1999-03-24 |
Zeneca Ltd |
Chemical compounds
|
GB9902453D0
(en)
|
1999-02-05 |
1999-03-24 |
Zeneca Ltd |
Chemical compounds
|
GB9902461D0
(en)
|
1999-02-05 |
1999-03-24 |
Zeneca Ltd |
Chemical compounds
|
GB9902459D0
(en)
|
1999-02-05 |
1999-03-24 |
Zeneca Ltd |
Chemical compounds
|
GB9902455D0
(en)
|
1999-02-05 |
1999-03-24 |
Zeneca Ltd |
Chemical compounds
|
KR100838617B1
(ko)
|
1999-02-10 |
2008-06-16 |
아스트라제네카 아베 |
혈관형성 억제제로서의 퀴나졸린 유도체
|
GB0000625D0
(en)
|
2000-01-13 |
2000-03-01 |
Zeneca Ltd |
Chemical compounds
|
DK1397130T3
(da)
*
|
2001-06-20 |
2007-11-12 |
Wyeth Corp |
Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
|
TWI224101B
(en)
*
|
2001-06-20 |
2004-11-21 |
Wyeth Corp |
Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
|
TWI317634B
(en)
*
|
2001-12-13 |
2009-12-01 |
Nat Health Research Institutes |
Aroyl indoles compounds
|
US7632955B2
(en)
*
|
2001-12-13 |
2009-12-15 |
National Health Research Institutes |
Indole compounds
|
US7528165B2
(en)
*
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
WO2003105847A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
AU2003256926A1
(en)
*
|
2002-07-26 |
2004-02-16 |
The Institutes For Pharmaceutical Discovery, Llc |
Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications
|
US7348351B2
(en)
*
|
2002-12-10 |
2008-03-25 |
Wyeth |
Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
|
UA80453C2
(en)
*
|
2002-12-10 |
2007-09-25 |
|
Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
JP2006510673A
(ja)
*
|
2002-12-10 |
2006-03-30 |
ワイス |
プラスミノゲンアクティベータインヒビター1(pai−1)のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換1h−インドール−3−イルグリオキシル酸誘導体
|
DE60306548T2
(de)
*
|
2002-12-10 |
2007-06-21 |
Wyeth |
Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
|
BR0316584A
(pt)
*
|
2002-12-10 |
2005-10-04 |
Wyeth Corp |
Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
|
ATE504568T1
(de)
*
|
2003-08-07 |
2011-04-15 |
Nat Health Research Institutes |
Indol-verbindungen als inhibitoren der tubulin- polymerisation zur behandlung von angiogenesisbezogenen erkrankungen
|
US7446201B2
(en)
*
|
2003-09-25 |
2008-11-04 |
Wyeth |
Substituted heteroaryl benzofuran acids
|
US7351726B2
(en)
*
|
2003-09-25 |
2008-04-01 |
Wyeth |
Substituted oxadiazolidinediones
|
US7163954B2
(en)
*
|
2003-09-25 |
2007-01-16 |
Wyeth |
Substituted naphthyl benzothiophene acids
|
US7582773B2
(en)
*
|
2003-09-25 |
2009-09-01 |
Wyeth |
Substituted phenyl indoles
|
US7442805B2
(en)
*
|
2003-09-25 |
2008-10-28 |
Wyeth |
Substituted sulfonamide-indoles
|
US7420083B2
(en)
*
|
2003-09-25 |
2008-09-02 |
Wyeth |
Substituted aryloximes
|
US7332521B2
(en)
*
|
2003-09-25 |
2008-02-19 |
Wyeth |
Substituted indoles
|
US7268159B2
(en)
*
|
2003-09-25 |
2007-09-11 |
Wyeth |
Substituted indoles
|
US7265148B2
(en)
*
|
2003-09-25 |
2007-09-04 |
Wyeth |
Substituted pyrrole-indoles
|
US7141592B2
(en)
*
|
2003-09-25 |
2006-11-28 |
Wyeth |
Substituted oxadiazolidinediones
|
US7342039B2
(en)
*
|
2003-09-25 |
2008-03-11 |
Wyeth |
Substituted indole oximes
|
US7534894B2
(en)
|
2003-09-25 |
2009-05-19 |
Wyeth |
Biphenyloxy-acids
|
US7411083B2
(en)
*
|
2003-09-25 |
2008-08-12 |
Wyeth |
Substituted acetic acid derivatives
|
GB0324763D0
(en)
*
|
2003-10-23 |
2003-11-26 |
Oxagen Ltd |
Use of compounds in therapy
|
US7186749B2
(en)
*
|
2004-08-23 |
2007-03-06 |
Wyeth |
Pyrrolo-naphthyl acids and methods for using them
|
BRPI0514572A
(pt)
*
|
2004-08-23 |
2008-06-17 |
Wyeth Corp |
ácidos de tiazolo-naftila
|
WO2006023865A1
(en)
*
|
2004-08-23 |
2006-03-02 |
Wyeth |
Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
|
JP2008521829A
(ja)
*
|
2004-11-30 |
2008-06-26 |
プレキシコン,インコーポレーテッド |
Ppar活性化合物
|
WO2006060535A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Plexxikon, Inc. |
Indole derivatives for use as ppar active compounds
|
JP4922946B2
(ja)
*
|
2004-12-21 |
2012-04-25 |
アボット・ラボラトリーズ |
カンナビノイド受容体リガンドとしての3−シクロアルキルカルボニルインドール類
|
US7456289B2
(en)
*
|
2004-12-31 |
2008-11-25 |
National Health Research Institutes |
Anti-tumor compounds
|
AU2006279496A1
(en)
*
|
2005-08-17 |
2007-02-22 |
Wyeth |
Substituted indoles and use thereof
|
US20070072904A1
(en)
*
|
2005-09-07 |
2007-03-29 |
Jack Lin |
PPAR active compounds
|
US8841334B2
(en)
*
|
2006-05-31 |
2014-09-23 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands and uses thereof
|
CA2647598A1
(en)
*
|
2006-05-31 |
2007-12-06 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands and uses thereof
|
JP5270542B2
(ja)
|
2006-07-22 |
2013-08-21 |
オキサジェン リミテッド |
Crth2アンタゴニスト活性を有する化合物
|
PE20090159A1
(es)
*
|
2007-03-08 |
2009-02-21 |
Plexxikon Inc |
COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
|
CN101765594A
(zh)
|
2007-03-28 |
2010-06-30 |
雅培制药有限公司 |
作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物
|
US7872033B2
(en)
*
|
2007-04-17 |
2011-01-18 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands
|
US8735434B2
(en)
*
|
2007-05-18 |
2014-05-27 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
US9193713B2
(en)
*
|
2007-10-12 |
2015-11-24 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
ES2442717T3
(es)
|
2008-01-18 |
2014-02-13 |
Atopix Therapeutics Limited |
Compuestos que tienen actividad antagonista de CRTH2
|
US7750027B2
(en)
*
|
2008-01-18 |
2010-07-06 |
Oxagen Limited |
Compounds having CRTH2 antagonist activity
|
WO2009093029A1
(en)
*
|
2008-01-22 |
2009-07-30 |
Oxagen Limited |
Compounds having crth2 antagonist activity
|
JP2011509990A
(ja)
*
|
2008-01-22 |
2011-03-31 |
オキサジェン リミテッド |
Crth2アンタゴニスト活性を有する化合物
|
GB2457040A
(en)
*
|
2008-01-30 |
2009-08-05 |
Oxagen Ltd |
1-Acetic acid indole derivatives with PGD2 activity
|
US8846730B2
(en)
*
|
2008-09-08 |
2014-09-30 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
US8188135B2
(en)
*
|
2008-09-16 |
2012-05-29 |
Abbott Laboratories |
Compounds as cannabinoid receptor ligands
|
PA8854001A1
(es)
*
|
2008-12-16 |
2010-07-27 |
Abbott Lab |
Compuestos novedosos como ligandos de receptores de canabinoides
|
CN103086943B
(zh)
*
|
2011-11-04 |
2015-04-15 |
山东亨利医药科技有限责任公司 |
作为crth2受体拮抗剂的吲哚类衍生物
|
US8715529B1
(en)
|
2012-01-23 |
2014-05-06 |
Arrowhead Center, Inc. |
Synthesis and applications of triazaborolopyridinium compounds and substituted triazaborolopyridinium compounds and methods of use
|
GB201322273D0
(en)
|
2013-12-17 |
2014-01-29 |
Atopix Therapeutics Ltd |
Process
|
GB201407807D0
(en)
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|
GB201407820D0
(en)
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|